Key Takeaways
- Revenue rebounds, margins stay compressed: Q4 FY23 revenue grew 26% YoY to ₹124.5 crore, but EBITDA margin fell to 13% from 22% a year ago, driven by a product mix shift away from high-margin SDAs and operational underutilization.
- The SDA reset is nearly complete: The segment that halved its contribution and crushed profitability has now worked through its high-cost inventory; the last dispatch from old stock leaves by end of May 2023, and demand is locked with large customers through December.
- A wave of commercializations lands late in FY24: Four large events, including four new SDAs and a major intermediate, go live from November 2023 onward, meaning the next 7–8 months deliver only incremental growth before a steep ramp.
- Management calls the bottom on surprises: The CEO stated this was "probably our last surprise," anchoring a 20–30% FY24 revenue growth guide and an 18–20% EBITDA margin target on a recovering product mix and new capacity absorption.
- What to watch next quarter: Whether the two electrolyte customers resume offtake in June as guided, whether flame retardant demand stabilizes by August–September, and whether the continuous flow plant clears its teething troubles by end of May.
SDA: The Margin Reset & Recovery
- Segment collapse drove the profit drop: SDA full-year revenue declined 43% YoY, shrinking from nearly 50% of revenue to ~30%; as the highest-margin segment, this mix shift was the dominant drag on consolidated EBITDA, which fell 44% for the full year.
- Inventory overhang now cleared: Consolidated inventory fell from ₹188.7 crore in September 2022 to ₹132.5 crore by March 2023; all excess SDA inventory will be consumed by end of May 2023, after which production runs on newly procured, lower-cost raw materials.
- Pricing mechanics protect spreads, not absolute profit: SDA spreads remain constant in percentage terms versus FY22; the lower absolute EBITDA is a function of plants running at low occupancy, where most costs are fixed. When raw material prices fall, customers demand price cuts immediately, compressing the rupee spread even if the percentage margin holds.
- Demand visibility is solid through year-end: Most SDA businesses are locked with large customers up to December 2023, and four new SDAs with a new customer enter commercialization from November onward at large volumes.
Chintan Shah: "See what has happened actually in this last 1.5 months, the price of two specific SDAs, which have prominent sales among all the product category, the key raw material prices started coming down from $19, today, it is being quoted at $13.5. So of course, the customer will also expect you to reduce the price based on the pricing formula that you have."
The FY24 Growth Bridge: Late-Stage Catalysts
- Four large events cluster at year-end: Four SDAs with a new customer commercialize from November 2023; one of the largest intermediate products goes commercial from January 2024, subject to a plant-scale trial dispatch by July/August 2023; and a newly approved product begins commercial orders by November/December 2023. The next 7–8 months see only incremental growth before these events hit.
- Electrolyte salts poised for a 100% growth year: One large customer, on hold for ~4 months while debottlenecking capacity, confirmed supply resumption from June 2023; the other customer, which had paused orders while sitting on inventory, has placed fresh orders this quarter. Two additional customers are in final stages of R&D sample submission for electrolyte solutions, and FY25 is expected to see robust growth as products commercialize.
- Continuous flow chemistry unlocks the PASC segment: Three products are on track for commercialization in Q4 FY24, offering a steep revenue increase; one has already received quality approval with plant-scale trial material planned for dispatch by end of August 2023 and commercial supplies from January 2024. A second product is in pilot trials with teething troubles expected to resolve by end of May 2023; the third product is expected to commercialize by July 2024.
- Underlying volume growth far exceeds reported revenue: Per an analyst's math, adjusting for the decline in finished product prices driven by raw material pass-through, underlying revenue growth is about 40-odd percent; management did not dispute this figure.
Margins: The Path Back to 18–20%
- Q4 gross margin took a one-time inventory hit: Gross margin dropped 400 bps sequentially, partly due to a ₹7–9 crore inventory loss from older intermediate-stage stock that required reprocessing with higher raw material and solvent costs.
- New plant underutilization was a structural drag: The Dahej SEZ facility operated at barely 5–10% capacity for the first six months, carrying fixed costs with negligible absorption; utilization is expected to reach 30–35% in FY24 and jump to 75–80% from January 2024 as commercializations kick in.
- Flame retardants will dilute margins near-term: Newly launched flame retardant products are a starting base product with low margins; the next-stage derivatives carry decent EBITDA, but the current mix will consume some margin from other categories. Revenue guidance of ₹40–50 crore for FY24 carries wide uncertainty because brominated flame retardant selling prices collapsed from ~$8 to $4.5 in six months.
- FY25 margin target set at 20–22%: Management sees FY24 EBITDA margins at 18–20% as a recovery year, with a safer FY25 number at 20–22%.
Chintan Shah: "I can assure you probably this was our last surprise."
Electrolyte Salts: The Next SDA?
- Segment grew 191% in FY23 off a tiny base: Electrolyte salts contributed ~4% of revenue in FY23, with two commercial customers currently active and four more in the pipeline at lab, pilot, and approval stages across two additional products.
- Customer resumption removes a near-term overhang: The customer that paused for capacity debottlenecking confirmed June 2023 restart; the second customer, which went dry last quarter after stocking inventory, has resumed ordering. A pilot-scale sample with another customer has been formally approved, with a plant-scale trial order targeted by October 2023.
- Margin profile matches SDA: Management stated electrolyte salts carry margins "more or less like SDA," making this segment the most promising lever for restoring consolidated profitability as it scales toward becoming a decent part of overall revenue in FY25.
- FY24 is the bridge year: Most new products will hit commercial supply only by end of FY24, so the real sales inflection is a FY25 story; FY24 growth is pegged at close to 100%, driven by existing customer resumption and initial new-customer trial volumes.
Pricing & Raw Material Dynamics
- Falling raw material prices compress revenue, not spreads: Key raw material prices dropped 15–25%, and because pricing is linked on a percentage basis, the spread remains constant in percentage terms while the absolute rupee spread shrinks. On two large customers' pricing models, the spread will increase by about 2% because of the overall price reduction, but not proportionately.
- Both pricing cycles hurt manufacturers: In rising markets, customers demand price holds until pending orders are executed; in falling markets, customers demand price cuts effective tomorrow. Management described this as being "always in trouble in both."
- Flame retardant pricing is uniquely volatile: Brominated flame retardant selling prices halved from ~$8 to $4.5 in six months, making revenue forecasting extremely difficult; customers are in wait-and-watch mode until raw material prices stabilize, with normalcy anticipated by August or September.
Chintan Shah: "Both the situations are not good for manufacturers. I can tell you that. We have passed through both the cycles. And when it's an increasing pricing cycle, customer wants you to hold the prices till you have executed all their pending orders. And when it's a falling pricing market, then customer wants a price change to happen from tomorrow. So you are always in trouble in both."
Capacity & Capex: Building for FY26
- Dahej SEZ commercial production commenced in April 2023: The expanded facility is now operational, but utilization will ramp slowly to 30–35% in FY24 before jumping to 75–80% from January 2024 as commercializations land.
- FY26 capacity absorption target: Management expects to run at ~85% occupancy by FY26, at which point new capex will be needed; planning and design for the next facility has already started, with execution expected to begin by end of December 2023 after being deferred due to the industry situation.
- Near-term capex is modest: A ₹16–17 crore investment for two columns and a couple of reactors is planned for the agro intermediate going into commercialization in 2024, with part of the chemistry running on a continuous flow basis.
- Continuous flow plant will take years to fill: The ideal state is running 365 days at full capacity, but management acknowledged it will take a couple of years to build the market to that level.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | 20–30% YoY growth (management calls this "definitely a conservative forecast") | FY24 |
| EBITDA margin | 18–20% range | FY24 |
| EBITDA margin | 20–22% ("safer number") | FY25 |
| SDA inventory clearance | All excess SDA inventory consumed; last dispatch from old stock by end of May 2023 | May 2023 |
| Electrolyte customer resumption | Large customer on hold for ~4 months to restart supplies | June 2023 |
| Continuous flow pilot fix | Teething troubles resolved, smooth pilot trial running | End of May 2023 |
| Continuous flow product trial dispatch | Plant-scale trial material dispatched for second product | End of August 2023 |
| Flame retardant demand normalcy | Customers expect decent demand mode | August–September 2023 |
| Four SDAs with new customer | Commercialization at large volumes | November 2023 |
| Newly approved product | Commercial orders begin | November–December 2023 |
| New capex execution | Planning and design started; execution begins | End of December 2023 |
| Continuous flow product commercial supply | Second product commercial supplies begin | January 2024 |
| Largest intermediate product | Commercialization, subject to plant-scale trial approval (dispatch by July/August 2023) | January 2024 |
| Dahej facility utilization | Ramp to 75–80% occupancy | From January 2024 |
| Electrolyte plant-scale trial | Trial order executed for pilot-approved customer | By October 2023 |
| PASC segment growth | ~75–80% growth from FY23 basis at current pricing | FY25 |
| Flame retardants revenue | ~₹200 crores (management notes this is difficult to forecast due to raw material price volatility) | FY25 |
| Electrolyte salts revenue inflection | Real sales growth begins to become a decent part of overall revenue | FY25 |
| Capacity absorption | ~85% occupancy, triggering need for next capex cycle | FY26 |
Key Metrics
| Metric | Q4 FY23 |
|---|---|
| Revenue from operations | ₹124.5 cr, +26% YoY |
| Full year FY23 revenue | ₹4,236 cr, -2% YoY |
| EBITDA | ₹16.3 cr, -26% YoY |
| EBITDA margin | 13%, vs 22% in Q4 FY22 |
| PAT | ₹17 cr, -3% YoY |
| PAT margin | 14%, vs 18% in Q4 FY22 |
| FY24 revenue growth guidance | 20%–30% |
| FY24 EBITDA margin guidance | 18%–20% |
| PTC segment revenue | ₹37.8 cr, full year ₹143.2 cr, +46% YoY |
| Electrolyte Salts segment revenue | ₹0.9 cr, full year ₹16.5 cr, +191% YoY |
| PASC segment revenue | ₹29.9 cr, full year ₹133.5 cr, +31% YoY |
| SDA segment revenue | ₹54.9 cr, full year ₹127.7 cr, -43% YoY |
| Exports | ₹304.2 cr (FY23), 72% of revenue |
| Consolidated inventory | ₹132.5 cr as on Mar 23, down from ₹188.7 cr as on Sep 22 |
| Working capital limit utilization | 71% of ₹220 cr sanctioned limits |
| IPO proceeds utilized | ₹195.3 cr of ₹207.28 cr, 94% utilized |
| New Dahej facility expected FY24 utilization | 30%–35% |
| Flame retardants FY24 revenue expectation | ₹40–50 cr |
| SDA FY24 revenue expectation | potentially hit same number as FY22 (approx ₹226 cr) |
| Electrolyte salts FY24 growth expectation | ~100% |
| PASC FY25 growth expectation | 75%–80% over FY23 |
| FY25 EBITDA margin expectation | 20%–22% |
| Effective tax rate FY24 | 17%–18%, assuming Dahej and Ankleshwar profit ratio of 2:1 |